Skip to main content
Equibles

EPRX · Eupraxia Pharmaceuticals Inc.

Track EPRX — free

Use EPRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EPRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.50 +0.55 (+7.91%)
Rebalance outlook locked
Market Cap
$459.21M
Shares
66.07M
Volume · Oct 20 215.7K Avg daily vol (3M) 622.28K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.95 Open$6.67 Day$6.67–7.05 52W close$5.33–9.10 Avg vol 30d791K Short int6.8M · 10.3% float · 11.1d Short vol66% DataApr 2024–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+17.8%
Year over year · more shares
Price change (1Y)
+20.2%
Trailing year
Short interest
10.3%
Latest settlement · 11.1 days to cover
View all 116 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −5%
below
Price vs 50-day avg −7%
below
RSI (14) 43
neutral
MACD trend Negative
52-week position 43%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −20%
trailing
6-month return −2%
trailing
YTD return −8%
this year
Relative strength −10%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow Accumulating
1 of 67 funds reported for Sep 30 · net +97 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.29% of float · ▼ -10.3% MoM · 11.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
67 holders — near 2-yr high, broad support
Squeeze score 76
high risk · 0–100
Fundamentals
Fair
EPS growth −36%
Y/Y
Balance sheet $80.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 66%
annualized · 1-yr
Max drawdown −36%
past year
ATR 7.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−5% Bearish
Price vs 50-day avg
−7% Bearish
RSI (14)
43 Neutral
MACD trend
Negative Bearish
52-week position
43% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow Accumulating
1 of 67 funds reported for Sep 30 · net +97 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.29% of float · ▼ -10.3% MoM · 11.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
67 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $5 Now $7 · 43% Range high $9
vs 200-day avg -5% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EPRX
Eupraxia Pharmaceuticals Inc.
this stock
$459.21M -7.9% — — 10.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +10.7% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +669.4% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +1.3% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
67
% held
37.5%
Reported
1 of 67
Top holder
Beutel, Goodman & Co Ltd.
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Falling
Shares short
6.8M
Days to cover
11.1d
Change
-783.6K sh
View
Short Volume
Short vol %
66%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
18.7K
Value
$155.5K
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
41.3%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-38.6M
EPS diluted
$-1.03
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 15, 2026
This year
31

Eupraxia reached enrollment of 120 patients in the blinded Phase 2b portion of the RESOLVE trial; over 3,000 injections have been administered with no treatment-related SAEs, and interim analysis is on track for December 2026.

View
Exempt Offerings
Offering
$1.9M
Filed
Nov 8, 2024
View
Earnings & Events
Webcasts
Last webcast
Jun 3, 2026
View

Performance

5D 20D 120D MTD YTD
EPRX -5.1% -19.6% -2.3% -23.6% -8.0%
SPY -1.5% -0.9% +7.7% +0.5% +12.4%
vs SPY -3.6% -18.7% -10.0% -24.1% -20.4%
Key facts CIK 1581178 CUSIP 29842P105 13F (30d) 1 filings 1 filers Visit website Investor relations